Healthcare entity
The clearest coverage concentration is telehealth: 2 of 3 stories, with the rest divided among 1 other category. Citi is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories. The 20-day window averages about 1.1 stories each week.
Last mentioned: Mar 17, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The clearest coverage concentration is telehealth: 2 of 3 stories, with the rest divided among 1 other category. Citi is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories. The 20-day window averages about 1.1 stories each week. Source depth averages 3 original sources per story, versus 3.4 across the same-window beat baseline. At 6, the average consequence score sits above the same-window beat average of 5.9. This profile follows 3 Healthcare stories mentioning Teladoc Health across the period from February 26, 2026 to March 17, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 398 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Teladoc Health. Shared-story counts are live from our verified record — not editorial picks.
A sharp sell-off in mid-cap healthcare stocks has pushed several key players into technically oversold territory as geopolitical tensions in the Middle East trigger a broader market retreat. Investors are rotating out of riskier mid-sized equities, creating potential entry points for value-oriented healthcare analysts.
Source: Seeking Alpha
Hims & Hers Health has secured a strategic partnership with Novo Nordisk to distribute branded GLP-1 medications, effectively ending a high-stakes patent dispute. The deal marks a pivotal shift for the telehealth provider from compounded alternatives to FDA-approved Ozempic, triggering a massive 41% rally in its share price.
Source: fool.com · Josh Kohn-Lindquist (us)
Teladoc Health (TDOC) shares experienced a significant uptick following positive market sentiment and broader gains in the healthcare technology sector. The movement comes as investors reassess the company's path to profitability and its competitive positioning against enterprise-grade health IT solutions like ServiceNow.
Source: markets.financialcontent.com · markets.financialcontent.com
Teladoc Health is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
